European venture capital poured into life sciences and medical technology in mid-October, with a single biotech firm pulling in €275 million to push rare disease treatments toward clinical trials.
The funding wave underscores a broader shift. Investors increasingly favor startups with tangible clinical milestones over speculative software plays, particularly in England where two of the largest rounds landed.
OMass Therapeutics, based in England, secured the week’s biggest haul. The €275 million investment will accelerate development of small molecule therapies targeting rare diseases and immunological conditions.
Meanwhile, Microbiotica raised €42 million. The clinical stage company plans to channel that capital into biologic treatments for inflammatory bowel disease.
Cardiac care also drew investor attention. Implicity pulled in €35 million for its remote heart monitoring platform. The company reported a 26% drop in patient mortality among users, a data point that likely strengthened its pitch.
Financial technology saw smaller but notable activity. Neonomics, a Norwegian open banking software firm, closed €3.56 million in growth funding. That raise followed a restructuring that slashed operating costs by nearly half.
Southern Europe’s investment ecosystem expanded as well. Panakès Partners launched an €8.5 million initiative in Italy to back early stage medtech and biotech companies. French venture manager Sofinnova Partners finalized its MD Start IV fund at €82 million, exceeding its target. The fund focuses on building medical technology startups from scratch.
Consolidation continued across digital health. Swiss health company Aeon acquired Aware Health, a deal that pushed Aeon’s total seed financing beyond €12 million.
As capital concentrates in clinically validated ventures, expect the gap between biotech winners and struggling software startups to widen across Europe.
